Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

35.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.5K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Positive Regulator Molecules02:39

Positive Regulator Molecules

5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Depletion of extracellular asparagine impairs self-reactive T cells and ameliorates autoimmunity in a murine model of multiple sclerosis.

eLife·2026
Same author

Distinct Source-Sink Patterns and Vertical Consumption of Alkyl and Aryl Organophosphate Esters in the Remote Ocean and Its Marginal Sea.

Environmental science & technology·2026
Same author

Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors.

bioRxiv : the preprint server for biology·2026
Same author

Epigenetic mechanisms of inflammatory memory in the central nervous system.

Nature immunology·2026
Same author

Efficacy and Safety of Bariatric Surgery in Acquired Hypothalamic Obesity: A Systematic Review and Individual Patient Data Meta-Analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026
Same author

Establishment of the China Elderly Comorbidity Medical Database (CECMed) and its application in machine learning-based prediction.

BMC geriatrics·2026

Video Experimental Relacionado

Updated: Jul 26, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

451

Moléculas de punto de control específicas de las células B que regulan la inmunidad antitumoral

Lloyd Bod1,2,3,4, Yoon-Chul Kye1,2,3, Jingwen Shi1,2,5

  • 1Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.

Nature
|June 21, 2023
PubMed
Resumen

Los investigadores descubrieron un subconjunto específico de células B que se expande durante el crecimiento del melanoma. Dirigirse a este subconjunto de células B que expresan TIM-1 inhibió significativamente el crecimiento tumoral y aumentó la inmunidad antitumoral.

Más Videos Relacionados

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

447
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.7K

Videos de Experimentos Relacionados

Last Updated: Jul 26, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

451
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

447
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.7K

Área de la Ciencia:

  • Inmunología
  • En el campo de la oncología
  • Biología celular

Sus antecedentes:

  • El papel de las células B en la inmunidad antitumoral no se comprende completamente.
  • Las inmunoterapias actuales se dirigen principalmente a las células T y a las células asesinas naturales.

Objetivo del estudio:

  • Investigar el papel de las células B en la inmunidad antitumoral durante la progresión del melanoma.
  • Para identificar subconjuntos específicos de células B involucradas en el crecimiento tumoral y la respuesta inmune.

Principales métodos:

  • Citometría de flujo de alto rendimiento
  • Secuenciación de ARN a granel y unicelular
  • Secuenciación de receptores de células B
  • Análisis de las células B durante el crecimiento del melanoma B16F10 en ratones

Principales resultados:

  • Se identificó un subconjunto en expansión de células B en el ganglio linfático de drenaje que expresa inmunoglobulina de células T y dominio de mucina 1 (TIM-1).
  • Este subconjunto también expresaba moléculas co-inhibidoras como PD-1, TIM-3, TIGIT y LAG-3.
  • La deleción selectiva de TIM- 1 (Havcr1) en las células B inhibió el crecimiento tumoral y mejoró las respuestas de las células T efectoras.
  • La pérdida de TIM-1 aumentó la respuesta al interferón tipo 1, aumentando la activación de las células B, la presentación de antígenos y la coestimulación, lo que condujo a una mayor expansión de las células T efectoras específicas del tumor.

Conclusiones:

  • Las células B que expresan TIM-1 juegan un papel crucial en la regulación de la inmunidad antitumoral.
  • Dirigir TIM-1 a las células B puede mejorar la inmunidad adaptativa e inhibir el crecimiento tumoral.
  • Esto pone de relieve una nueva estrategia para la inmunoterapia del cáncer mediante la participación de las células B.